AZN AstraZeneca PLC
Company Analysis
Latest News
AstraZeneca Wins FDA Approval for Etcamah, Cutting Cancer Progression Risk 56%
The FDA granted accelerated approval to AstraZeneca’s Etcamah (camizestrant) for adults with HR-positive, HER2-negative advanced breast cancer. This approval...
AstraZeneca, Daiichi Sankyo win EU approval for Enhertu, first regimen in decade
The European Commission approved AstraZeneca and Daiichi Sankyo’s Enhertu, combined with pertuzumab, for first-line treatment of unresectable or metastatic...
AstraZeneca hits Phase III goals for Tagrisso combo, boosting lung cancer survival
AstraZeneca and HUTCHMED reported positive results from the SANOVO Phase III trial in China. The study evaluated Tagrisso (osimertinib) combined with Orpathys...
AstraZeneca secures $1.5B rights for Zegfrovy, targeting rare lung cancer mutations
AstraZeneca finalized an exclusive global licensing agreement with Dizal Pharmaceutical for the lung cancer drug Zegfrovy. The deal grants AstraZeneca...
AstraZeneca Advances Datroway to Phase 3, Targeting High-Risk Urothelial Cancer
AstraZeneca and Daiichi Sankyo dosed the first patient in the TROPION-Urothelial04 Phase 3 clinical trial. The study evaluates Datroway (datopotamab...
🟢 AstraZeneca is trading 3.02% up today after positive Tagrisso and Enhertu lung-cancer results
AstraZeneca is trading 3.02% up at $164.93 after positive Phase III results for Tagrisso plus savolitinib and Enhertu in non-small-cell lung cancer. -...
AstraZeneca Halts Volrustomig Lung Cancer Trial, Threatening Revenue Targets
AstraZeneca terminated its Phase III eVOLVE-Lung02 clinical trial for volrustomig combined with chemotherapy. The study evaluated the regimen as a first-line...
AstraZeneca beats standard care, hitting first-line lung cancer milestone with Enhertu
AstraZeneca and Daiichi Sankyo announced that Enhertu met its primary endpoint in the DESTINY-Lung04 Phase III trial. The study evaluated Enhertu as a...
AstraZeneca PLC Q2 2026 Earnings Preview: What Analysts Expect on July 27, 2026
Consensus estimates for Q2 2026 project revenue at $15.45 billion and earnings at $2.50 per share, as the current stock price of $169.26 trades significantly...
Healthcare Movers: Key Drug Approvals and Corporate Updates
The healthcare sector saw key regulatory and corporate news this week. AstraZeneca received U.S. FDA approval for Baxfendy, a first-in-class drug for...
AstraZeneca PLC Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
AstraZeneca is projected to report Q1 2026 revenue of $14.98 billion and core EPS of $2.57, with its current stock price of $189.71 trading below the average...